Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials

Matthew J. Maurer, Hervé Ghesquières, Brian K. Link, Jean Philippe Jais, Thomas M. Habermann, Carrie A. Thompson, Corinne Haioun, Cristine Allmer, Patrick B. Johnston, Richard Delarue, Ivana N. Micallef, Frederic Peyrade, David J. Inwards, Nicolas Ketterer, Umar Farooq, Olivier Fitoussi, William R. Macon, Thierry J. Molina, Sergei Syrbu, Andrew L. FeldmanSusan L. Slager, George J. Weiner, Stephen M. Ansell, James R. Cerhan, Gilles A. Salles, Thomas E. Witzig, Hervé Tilly, Grzegorz S. Nowakowski

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Fingerprint

Dive into the research topics of 'Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials'. Together they form a unique fingerprint.

Medicine & Life Sciences